All the news Showing 10 of 40 articles from: Side effectsGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Patients with HCV may deliberately skip early treatment doses when feeling well Healio Hepatology / 26 March 2013 Adherence to hepatitis C treatment: unravelling the complexities Rob Camp / 13 December 2012 Successful adherence to hepatitis C treatment may require physicians and care teams to address a wide range of factors, according to research from the United States and Germany presented at The Liver Meeting ... Hepatitis C patients with cirrhosis respond well to boceprevir or telaprevir with careful monitoring Liz Highleyman / 05 December 2012 Real-world experience in the French early-access CUPIC cohort shows that hepatitis C patients with advanced liver damage can achieve good response to interferon-based triple-therapy including boceprevir (Victrelis) or telaprevir (Incivo), researchers reported ... Reducing ribavirin and adding EPO are both good anaemia management strategies for people taking boceprevir Liz Highleyman / 13 November 2012 Chronic hepatitis C patients treated with boceprevir (Victrelis) plus pegylated interferon and ribavirin can effectively manage drug-induced anaemia by either ribavirin dose reduction or addition of erythropoietin (EPO) without compromising treatment effectiveness, researchers ... European guidelines on management of mental health for people with hepatitis C published Michael Carter / 16 October 2012 European investigators have developed a consensus statement on hepatitis C and mental health. Published in the online edition of the Journal of Hepatology, the wide-ranging document assesses evidence concerning the effect of hepatitis C ... Ribavirin dose reduction is effective for managing anaemia in patients using boceprevir or telaprevir Liz Highleyman / 11 May 2012 Reducing the dose of ribavirin and adding erythropoietin are both good options for managing anaemia in hepatitis C patients treated with boceprevir (Victrelis) triple therapy, according to study findings presented at the 47th ... Depression and pegylated interferon: doctors look at screening strategies and treatment Michael Carter / 09 May 2012 Patients with hepatitis C should be carefully evaluated for symptoms of depression before and during pegylated interferon-based therapy, investigators write in the International Journal of Interferon, Cytokine and Mediator Research. The authors also highlighted ... Telaprevir and boceprevir show high rate of serious side-effects in hepatitis C patients with urgent need of treatment Keith Alcorn / 20 April 2012 A real-world study of new hepatitis C protease inhibitors in the group of patients who have been told they should not wait for newer, experimental antivirals has shown a much higher rate ... Common side-effects of hepatitis C protease inhibitors: clinical management advice published Michael Carter / 20 January 2012 The addition of the protease inhibitors telaprevir or boceprevir to hepatitis C treatment regimens increases the risk of anaemia, according to a review article published in Liver International. The author also found that ... Coffee consumption reduces side-effects in people on hepatitis C treatment Gus Cairns / 14 September 2011 Drinking three or more cups of coffee a day reduced the incidence of self-reported side-effects by more than 80% compared to non-coffee drinkers in people co-infected with hepatitis C and HIV who were taking ... ← Prev1234Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Transmission and prevention Diagnosis and monitoring Disease course and symptoms HCV and coinfections Living with HCV Treatment issues Side effects Therapies Liver transplants Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive